<DOC>
	<DOCNO>NCT02165046</DOCNO>
	<brief_summary>Budesonide + Procaterol HFA MDI novel asthma product contain budesonide procaterol single inhaler . Budesonide corticosteroid treat underlie airway inflammation asthma . Procaterol direct act sympathomimetic predominantly Beta-adrenoceptor stimulant activity selective Beta-2 receptor ( Beta-2 agonist ) . It use bronchodilator management reversible airway obstructive pulmonary disease . Budesonide Procaterol therefore complementary effect , treat two different component asthma .</brief_summary>
	<brief_title>Bioavailability Study SYN006 , Pulmicort pMDI Meptin Air Healthy Adult .</brief_title>
	<detailed_description>Test drug : SYN006 HFA MDI ( Budesonide + Procaterol Hydrochloride ) Strength : ( Budesonide 180ug Procaterol Hydrochloride 10ug/puff ) Mode administration : Orally inhaled administration , single dose ( 4 puff ) Reference drug 1 : Pulmicort pMDI ( Budesonide ) Strength : ( Budesonide 200ug/puff ) Mode administration : Orally inhaled administration , single dose ( 4 puff ) Reference drug 2 : Meptin Air 10ug ( Procaterol Hydrochloride ) Strength : ( Procaterol Hydrochloride 10ug/puff ) Mode administration : Orally inhaled administration , single dose ( 4 puff ) One dose drug ( Test , Reference 1 Reference 2 ) least 6-day washout period .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Procaterol</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Provision sign write informed consent enrollment study , ability communicate investigator , understand comply requirement study . 2 . Healthy adult , age 20 40 year old . 3 . Subjects Body Mass Index ( BMI ) ≧18.5 ≦25.0 ( BMI calculate weight kilogram [ kg ] /height meters2 [ m2 ] ) . 4 . Physically mentally healthy subject confirm interview , medical history , clinical examination , chest xray electrocardiogram . 5 . No significant deviation normal biochemistry examination . 6 . No significant deviation normal hematology examination . 7 . No significant deviation normal urinalysis examination . 1 . History drug alcohol abuse within past year . 2 . Medical history severe drug allergy sensitivity analogous drug . 3 . Evidence acute chronic disease undergo surgery 4 week prior Period I dose . 4 . Evidence clinical significant renal , cardiovascular , hepatic , hematopoietic , neurological , pulmonary gastrointestinal pathology . 5 . Planned vaccination time course study . 6 . Taking clinical investigation drug 2 month prior Period I dose . 7 . Use medication , include herb medicine 4 week dose . 8 . Donation 500 mL blood past 3 month prior dose donation 250 mL blood past 2 month prior dose . 9 . A positive Hepatitis B surface antigen positive Hepatitis C antibody result . 10.A positive test HIV antibody . 11.In screening subject give train ensure subject able correctly use investigational product . If subject , use investigational product lack proficiency include study . 12.Students National Defense Medical Center . 13.For female subject , meet follow criterion : 1 . Lactating woman 2 . Positive pregnancy test ( urine ) screening , prior dose 3 . Do use adequate contraception study 4 . Women take oral contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>